Please assess the completion status of the following clinical trial:

Trial Title: Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have an active malignancy defined as any of: a) Diagnosis of cancer (excluding basal cell or squamous cell carcinoma of the skin) within 18 months of enrollment; b) Have received treatment for cancer within 18 months (e.g. radiation therapy, chemotherapy, adjuvant therapy); c) Have documented recurrent or metastatic cancer~* Receiving a 3-6 month course of weight-adjusted LMWH for an acute, objectively confirmed, symptomatic VTE (proximal or distal DVT of the lower extremity, proximal DVT of the upper extremity, or PE)~* Age ≥ 18 years~* Life expectancy \> 6 months~* Able to comply with scheduled follow up visits~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Willing to provide written informed consent~Exclusion Criteria:~* Distal DVT of the upper extremity~* Recurrent VTE during the 3-6-month LMWH treatment period~* Major or clinically relevant non-major bleeding during the 3-6 month LMWH treatment period~* Risk of bleeding (e.g. recent neurosurgery, history of intracranial hemorrhage, acute gastroduodenal ulcer, etc.)~* Diagnosis of basal cell and squamous cell carcinoma of the skin or acute Leukemia~* Platelet count \< 50 x 109/L~* Creatinine clearance \<30ml/min (using the modified Cockcroft-Gault formula)~* On hemodialysis~* Known hypersensitivity to heparin, LMWHs, or pork products~* Known contraindication to the use of heparin (e.g. heparin-induced thrombocytopenia)~* Currently participating in another clinical trial involving anticoagulation therapy (with the exception of aspirin)~* Pregnancy or breastfeeding~* On an anticoagulant for a different indication~* Treating physician plans for weight-adjusted LMWH for longer than 3-6 months duration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).